Careful about extrapolating the results of currently reported vaccine trials. See:
"Cancer Vaccines in Glioma: How to Balance the Challenges of Small Trials, Efficiency, and Potential Adverse Events"
http://jco.ascopubs.org/content/28/31/4670.full.pdf+html
Also, the criteria for selection as a trial participant may innately select those who statistically will have a longer survival time, its called selection bias and is nearly always a problem. Fortunately, there is underway appropriately designed trials. It would take at least 2 years of following the trial patients to see if the tumor will evolve mutations to which the vaccine is not directed, thus escaping the immunization therapy.